Pre-clinical work in bladder cancer [49, 59] and extensive studies in other cancers [60–63] suggest that MEK inhibition could be a potential combination approach to PI3K/AKT/mTOR inhibition, by targeting a parallel compensatory pathway. The gene discussed is MAP2K7; the disease is urinary bladder carcinoma.